NLRP3 and cryopyrin-associated periodic syndrome: An alternative therapeutic approach for treating diseases associated with ZNFX1 deficiency could involve pharmacological suppression of the NLRP3 inflammasome, such as through the use of anti-IL-1 therapy in CAPS patients (Booshehri and Hoffman, 2019).